Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Guangzhou Medical University | China

Prof. Lingmin Zhang is a leading researcher whose work integrates pharmaceutics, biomedical materials, and gene delivery, contributing significantly to advanced therapeutic strategies, particularly in lung cancer and inflammatory diseases. With 3,077 citations , 79 publications, and an h-index of 27, the researcher's scholarly impact is widely recognized. The work focuses on innovative nano-based and biomimetic delivery platforms, including nano-PROTACs, exosomes, microfluidic nanovesicles, and CRISPR/Cas9 carriers, offering transformative possibilities for targeted and precision medicine. Supported by major grants from the National Natural Science Foundation of China (projects 82572415, 82072047, 81700382), the researcher has developed cutting-edge strategies such as reprogramming tumor-associated macrophages, overcoming drug resistance in lung cancer, and reversing epigenetic silencing through nanoparticle-mediated gene delivery. Influential publications in high-impact journals—including Journal of Controlled Release, Drug Resistance Updates, ACS Nano, Angewandte Chemie, Advanced Science, and Molecular Cancer—highlight breakthroughs in nano-therapeutics, PROTAC technologies, artificial exosomes, and nucleic-acid delivery systems. Collectively, these contributions position the researcher at the forefront of translational nanomedicine, with ongoing work offering new directions for precision oncology, regenerative strategies, and next-generation drug delivery platforms.

Profile : Scopus | Orcid

Featured Publication

He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., Su, J., & Zhang, L. (2026). In situ reprogramming of tumor associated macrophages with versatile nano-epigenetic inhibitor for lung cancer therapy. Journal of Controlled Release, 2026, 114497.

Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. (2026). The novel strategy to overcome drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates, 84, 101316.

Chen, S., Chen, E., Su, J., Gong, Y., Tang, S., Qin, A., Shen, A., Tang, S., & Zhang, L. (2025). Magnetically navigated nano-PROTAC ameliorates acute lung injury. Journal of Nanobiotechnology, 23, 622.

Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025). Microfluidics-assembled nanovesicles for nucleic acid delivery. Accounts of Chemical Research, 58, 570–582.

Liang, L., Peng, W., Qin, A., Zhang, J., Chen, R., Zhou, D., Zhang, X., Zhou, N., Yu, X., & Zhang, L. (2024). Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano, 18(32), 21009–21023.

Guan, X., Xu, X., Tao, Y., Deng, X., He, L., Lin, Z., Chang, J., Huang, J., Zhou, D., Yu, X., Wei, M., & Zhang, L. (2024). Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. Journal of Nanobiotechnology, 22, 692.

Zhang, L., Lin, Y., Li, S., Guan, X., & Jiang, X. (2023). In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angewandte Chemie International Edition, 62(11), e202217089.

Liang, L., Cen, H., Huang, J., Qin, A., Xu, W., Wang, S., Chen, Z., Tan, L., Zhang, Q., Yu, X., Yang, X., & Zhang, L. (2022). The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Molecular Cancer, 21(1), 186.

Zhang, H., Peng, R., Chen, S., Shen, A., Zhao, L., Tang, W., Wang, X., Li, Z., Zha, Z., Yi, M., & Zhang, L. (2022). Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Advanced Science, 9(29), 2202039.

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019). Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angewandte Chemie International Edition, 58(36), 12404–12408.

Adarsh Kumar Shukla | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Dr. Adarsh Kumar Shukla | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Dr. Bhimrao Ramji Ambedkar Government Medical College | India

Author Profile

Scopus

Orcid

Google Scholar

 

Early Academic Pursuits

Dr. Adarsh Kumar Shukla laid the foundation of his academic journey with a strong inclination towards life sciences and biological research. Beginning with a degree in Biotechnology, he cultivated a passion for understanding molecular processes and biological systems. His interest in computational and applied biological sciences further deepened during his Master’s studies in Bioinformatics, where he explored the integration of biology with computational technologies. This academic progression culminated in a doctoral degree in Nutrition Biology from the Central University of Haryana, where he investigated nutraceutical compounds, molecular therapeutics, and bioinformatics-based approaches to health and nutrition. His early academic pursuits reflect a strong balance between theoretical learning, laboratory training, and computational applications in life sciences.

Professional Endeavors

Dr. Shukla’s professional career demonstrates a consistent alignment with advanced biomedical research and innovation. He began as a Research Associate and later served as a Scientist in the Department of Paediatric Cardiac Research at Sri Sathya Sai Sanjeevani Research Foundation, contributing to projects on congenital heart diseases and molecular mapping of environmental toxicants. His current role as Scientist-B in the Multidisciplinary Research Unit at Dr. Bhimrao Ramji Ambedkar Government Medical College, Kannauj, highlights his continued commitment to translational biomedical research. Alongside, he has engaged in teaching and faculty development programs, coordinated national scientific conclaves, and participated in capacity-building initiatives in healthcare and nutrition sciences.

Contributions and Research Focus

Dr. Shukla’s research spans a wide spectrum, encompassing structural bioinformatics, human genomics, and nutritional biology. His investigations range from identifying novel bioactive compounds in millets and medicinal plants to computationally mapping toxicants responsible for congenital disorders. His work on psychobiotics and gut-brain regulation has added new insights into neuropsychological health, while his contributions in plant-informatics shed light on the therapeutic potential of natural compounds against viral and bacterial diseases. Additionally, his focus on food-informatics and nutrigenomics has emphasized the role of probiotics, dietary fibers, and bioengineered foods in human health. Through a combination of in-silico and in-vitro studies, his work bridges computational biology with clinical and nutritional sciences.

Accolades and Recognition

Over the course of his career, Dr. Shukla has been recognized for his scientific excellence through awards, patents, and international presentations. He achieved distinction at global scientific forums, securing recognition for his molecular insights into congenital heart disease. His granted Indian patent on crab-apple-based jelly sheets demonstrates his inventive ability to connect traditional resources with modern food biotechnology. Furthermore, his peer-review contributions for high-impact journals and invited roles as a book reviewer underline his standing in the academic community. These achievements illustrate his ability to merge innovation with scholarly rigor.

Impact and Influence

The impact of Dr. Shukla’s research is evident in the interdisciplinary nature of his contributions. His computational models for drug discovery, therapeutic peptides, and congenital heart disease targets provide frameworks for future translational research. His coordination of events such as National Nutrition Month and Women in STEM conclaves reflects his commitment to societal awareness and academic empowerment. By blending computational biology with real-world health challenges, he has influenced research directions in reproductive toxicology, nutraceutical development, and environmental genomics, thereby shaping both scientific knowledge and public health practices.

Legacy and Future Contributions

Dr. Shukla’s academic and professional trajectory reflects the making of a researcher whose work is deeply rooted in societal relevance and interdisciplinary innovation. His legacy lies in advancing computational nutrition biology and medical informatics to address complex health challenges. Looking ahead, his ongoing projects on congenital heart disease, exposome mapping, and nutratherapeutics hold the promise of contributing to precision medicine and sustainable food innovations. His future contributions are likely to expand the integration of bioinformatics with clinical sciences, reinforcing his role as a bridge between molecular insights and healthcare applications.

Present Affiliation

Dr. Adarsh Kumar Shukla is currently serving as Scientist-B in the Multidisciplinary Research Unit at Dr. Bhimrao Ramji Ambedkar Government Medical College, Kannauj, Uttar Pradesh. His role reflects his dedication to advancing multidisciplinary biomedical research with a focus on translational outcomes for healthcare.

Publications

Article: Computational insights into maternal environmental pollutants and folate pathway regulation
Authors: Adarsh Kumar Shukla, Shadab Ahamad, Prachi Kukshal
Journal: Reproductive Toxicology
Year: 2025

Article: Virtual screening of potential orally active anti-bacterial compounds of finger millet
Authors: Raushan Kumar Jha, Adarsh Kumar Shukla, Anita Kumari, Ashwani Kumar
Journal: Vegetos
Year: 2024

Article: Identification of micronutrient deficiency related miRNA and their targets in Triticum aestivum using bioinformatics approach
Authors: Surbhi Panwar, Sunita Pal, Adarsh Kumar Shukla, Ashwani Kumar, Pradeep Kumar Sharma
Journal: Ecological Genetics and Genomics
Year: 2024

Article: Effect of processing techniques on functional, antioxidants, and structural properties of finger millet (Eleusine coracana) flour
Authors: Arzoo, Neeru, Adarsh Kumar Shukla, Surbhi Panwar, Ashwani Kumar
Journal: Food and Humanity
Year: 2024

Article: Nutritional evaluation of probiotics enriched rabadi beverage (PERB) and molecular mapping of digestive enzyme with dietary fibre for exploring the therapeutic potential
Authors: Prakash Yadav, Adarsh Kumar Shukla, Deepika, Neeru, Anita Kumari, Tejpal Dhewa, Ashwani Kumar
Journal: Food and Humanity
Year: 2024

Conclusion

In summary, Dr. Shukla embodies the qualities of a multidisciplinary scientist who blends innovation with social responsibility. His research not only advances scientific understanding but also carries tangible implications for human health and nutrition. With his current role in a government medical research unit and his wide-ranging expertise, he is poised to make enduring contributions to biomedical sciences, food biotechnology, and public health.

Abdelaziz Ghanemi | Medicine and Dentistry | Best Researcher Award

Published on by Book of Award

Dr. Abdelaziz Ghanemi | Medicine and Dentistry | Best Researcher Award

Laval University | Canada

Author Profile

Orcid

Google Scholar

🎓 Early Academic Pursuits

Dr. Abdelaziz Ghanemi’s academic foundation reflects both intellectual rigor and global engagement. He graduated as the top student from the pharmacy program at Mentouri University of Constantine in Algeria. His quest for advanced scientific knowledge led him to China Pharmaceutical University, where he earned a Master of Science in Pharmacology, completing more than twice the credit requirement. His research there involved high-throughput screening for dopamine D5 receptor ligands—a project using transgenic cell lines and cutting-edge fluorescence assays. He then pursued a Ph.D. in Molecular Medicine at Laval University in Canada. His doctoral thesis was a comprehensive study of gene regulation in obesity and exercise, particularly focusing on TFF2 and SPARC, and was constructed from an impressive 27 peer-reviewed publications, marking an extraordinary achievement in biomedical research.

🧪 Professional Endeavors

Dr. Ghanemi’s professional journey spans Algeria, China, and Canada, covering a spectrum of scientific, academic, and community roles. His appointments include:

👨‍🔬 Postdoctoral Fellowships at CHU de Québec–Université Laval Research Center and LOEX Regenerative Medicine Lab, where he explored obesity, vascular calcification, and 3D bioprinting for tissue engineering.
👨‍🏫 Visiting Scholar at the University of Victoria (2024), working under Prof. Stephanie Willerth on bioprinting applications in regenerative medicine.
🔬 Research Professional at the CHUQ’s Functional Genomics and SAGE platform, applying gene expression tools to decode metabolic and ageing pathways.
🌍 Interpreter and Science Communicator, fluent in Arabic, English, French, and Chinese, enhancing cross-cultural scientific collaboration.

In addition to these, Dr. Ghanemi has participated in numerous internships, including hospital pharmacy and neurobiology labs, and taught pharmacology in China—demonstrating both practical and pedagogical expertise.

🔬 Contributions and Research Focus

Dr. Ghanemi’s research covers some of the most pressing biomedical themes of our time:

🧠 Obesity and metabolism, focusing on gene-environment interactions and exercise-induced molecular changes
💪 Regenerative medicine, especially the roles of SPARC and TFF2 in ageing, obesity, and tissue repair
🧬 Genomic and transcriptomic analysis using transgenic animal models and advanced sequencing platforms
🩺 Chronic kidney disease and mineral bone disorders, examining vitamin D pathways and Wnt/β-catenin signaling

His scholarly productivity includes over 50 scientific articles, a Google Scholar h-index of 22, and contributions to high-impact journals such as Biomedicines, Metabolites, Biology, Medicines, and Cytokine.

🏅 Accolades and Recognition

Dr. Ghanemi’s excellence has been recognized globally:

🥇 “Best Student Award” during his undergraduate pharmacy studies
🏆 Oral Presentation Award at ICOMES & AOCO 2019 in Seoul for research on SPARC and exercise
🎓 Vanier Canada Graduate Scholarship Nominee, one of Canada’s most prestigious honors
💬 “Student Seminar Award” by CHU de Québec Research Center for outstanding research communication
🏅 “I Stand With Her” Award at the Women in Medicine Summit (Chicago), honoring his advocacy for women's health
🌍 Laval University Representative at the Canadian Student Health Research Forum (2021)

These distinctions underscore both the scientific value and societal impact of his work.

🌐 Impact and Influence

Dr. Ghanemi’s influence extends beyond the laboratory. His work on exercise mimetics, bioenergetics, and gene-environment crosstalk holds implications for public health, geriatrics, and personalized medicine. As an editor for a special issue in Biomedicines (2024–2025), he is shaping academic dialogue on metabolism and tissue engineering. His editorial contributions and published opinions have influenced how we view obesity, exercise biology, and post-COVID metabolic health. His multilingual ability and international collaborations make him a bridge between cultures and scientific communities.

🔮 Legacy and Future Contributions

Dr. Ghanemi's trajectory suggests a lasting legacy in translational medicine. His integration of molecular research, clinical relevance, and public health awareness positions him to advance therapeutic development in obesity, regenerative strategies, and age-related diseases. With current projects involving SPARC’s therapeutic applications, vascular biology, and bioprinted tissues, Dr. Ghanemi is at the vanguard of modern biomedical science. His commitment to publishing, mentoring, and interdisciplinary exploration signals continued contributions to global health and scientific progress.

Publications

📄 A Single Intraperitoneal Secreted Protein Acidic and Rich in Cysteine Injection in Mice Is Towards an Exercise-like Phenotype
Authors: Abdelaziz Ghanemi, Mayumi Yoshioka, Jonny St-Amand
Journal: Biology
Year: 2025

📄 Obesity and Bone Mineral Density Protection Paradox in Chronic Kidney Disease: Secreted Protein Acidic and Rich in Cysteine as a Piece of the Puzzle?
Authors: Abdelaziz Ghanemi, Fabrice Mac-Way
Journal: Life
Year: 2023

📄 Secreted Protein Acidic and Rich in Cysteine (SPARC) to Manage Coronavirus Disease-2019 (COVID-19) Pandemic and the Post-COVID-19 Health Crisis
Authors: Abdelaziz Ghanemi, Mayumi Yoshioka, Jonny St-Amand
Journal: Medicines
Year: 2023

📄 Secreted Protein Acidic and Rich in Cysteine (SPARC)—Mediated Exercise Effects: Illustrative Molecular Pathways against Various Diseases
Authors: Abdelaziz Ghanemi, Mayumi Yoshioka, Jonny St-Amand
Journal: Diseases
Year: 2023

📄 DNA Damage as a Mechanistic Link between Air Pollution and Obesity?
Authors: Abdelaziz Ghanemi, Mayumi Yoshioka, Jonny St-Amand
Journal: Medicines
Year: 2022

Bin Zheng | Biomedicine | Best Researcher Award

Published on by Book of Award

Prof. Dr. Bin Zheng | Biomedicine | Best Researcher Award

Tianjin University | China

Author Profile

Scopus

Orcid

Early Academic Pursuits 🌱

Prof. Dr. Bin Zheng’s academic journey began with a solid foundation in medical engineering and translational medicine. He further honed his expertise as a postdoctoral fellow at the Caroline School of Medicine, Sweden, laying the groundwork for a prolific career. His early pursuits in biomaterials and nanotechnology provided a strong base for his subsequent innovations and contributions to biomedical sciences.

Professional Endeavors 🏢

As a professor at Tianjin University's Academy of Medical Engineering and Translational Medicine, Dr. Zheng has led numerous research projects, including 10 completed and 6 ongoing endeavors. With over 30 impactful SCI publications, his work has gained recognition on a global scale. His collaborations with leading companies have fostered breakthroughs in cellular manufacturing and delivery technologies, enhancing both academic and industrial applications.

Contributions and Research Focus 🔬

Dr. Zheng’s work spans a wide range of fields, including biomaterials, cancer research, cellular microbiology, immunity, and nanobiotechnology. He has developed innovative therapeutic agents, including a nebulizable anti-bacterial spray targeting exosomes and stem cell extracts. His patents—70 published and 14 in progress—reflect his commitment to bridging the gap between laboratory research and clinical application.

Accolades and Recognition 🏆

Dr. Zheng’s outstanding contributions have earned him numerous awards, such as the Excellent Doctoral Dissertation of Tianjin Municipality and the First Prize for Innovative Achievements from the China Industry-University-Research Cooperation Association. Under his mentorship, graduate students have garnered over 20 prestigious awards, solidifying his role as an influential academic leader.

Impact and Influence 🌍

His research has been clinically translated and widely reported by media outlets like Science and Technology Daily and Science Net. As an editorial board member of prestigious journals, Dr. Zheng also influences the direction of global biomedical research. His international collaborations and contributions to standards like the Belt and Road LSEA 0006-2022 standard underscore his global impact.

Legacy and Future Contributions 🌟

Prof. Dr. Bin Zheng’s legacy lies in his innovative methodologies and translational focus, which continue to inspire the next generation of researchers. With ongoing projects in cutting-edge fields like optogenetics and cellular precision manufacturing, his future contributions are set to redefine the boundaries of medical engineering and translational medicine.

 

Publications

📄 Microorganism microneedle micro-engine depth drug delivery
Author(s): Zheng, B., Li, Q., Fang, L., Cheng, S.-X., Zhang, X.
Journal: Nature Communications
Year: 2024

📄 Near-infrared remote triggering of bio-enzyme activation to control intestinal colonization by orally administered microorganisms
Author(s): Sun, W., Yun, F., Guo, Q., Zheng, B., Ruan, X.
Journal: Acta Biomaterialia
Year: 2024

📄 Surface nanocoating-based universal platform for programmed delivery of microorganisms in complicated digestive tract
Author(s): Du, Y., Guo, H.L., Su, X., Wang, T., Zheng, B.
Journal: Journal of Colloid and Interface Science
Year: 2024

📄 A self-assembling bioactive oligopeptide hydrogel for the treatment of edema following prepuce surgery
Author(s): Liu, J., Pei, Y., Huang, Y., Chen, L., Zhou, Y.
Journal: Journal of Materials Chemistry B
Year: 2024

📄 NIR-Remote Selectively Triggered Buprenorphine Hydrochloride Release from Microneedle Patches for the Treatment of Neuropathic Pain
Author(s): Han, H., Li, B., Yang, R., Bai, Y., Yu, Y.
Journal: ACS Biomaterials Science and Engineering
Year: 2024

 

Inmaculada Gilaberte | Medicine and Dentistry | Best Researcher Award

Published on by Book of Award

Dr. Inmaculada Gilaberte | Medicine and Dentistry | Best Researcher Award

FAES Farma | Spain

Author Profile

Scopus

🌱 Early Academic Pursuits

Dr. Inmaculada Gilaberte’s academic journey is rooted in a commitment to excellence and medical advancement. She initially pursued education in clinical research, equipping herself with in-depth knowledge and skills in therapeutic areas such as neuroscience and immunology. Her academic foundation was further strengthened by certifications, including a lecturer certification from the Spanish Quality Register Agency (ANECA), and advanced leadership programs from institutions like Stanford and MIT. These formative experiences shaped her growth mindset, laying the groundwork for a career dedicated to precision, patient-centered care, and effective team collaboration.

💼 Professional Endeavors

Throughout her career, Dr. Gilaberte has held prominent roles in major pharmaceutical companies such as FAES FARMA, Takeda, TiGenix, Roche, and Lilly, with positions spanning from Clinical Research Physician to Director of Clinical Research. She has led various departments, managed global teams, and directed clinical trials across multiple therapeutic areas, including gastroenterology, immunology, cardiology, and pain management. Her strategic guidance has driven several landmark projects forward, including the advancement of microbiome and cell therapies from preclinical to first-in-human trials, demonstrating her expertise in transforming innovative therapies into viable treatment options.

🧬 Contributions and Research Focus

Dr. Gilaberte has made notable contributions to clinical research, particularly in stem cell therapy, immunology, and neuroscience. Her pioneering work on Darvadstrocel, an allogeneic adipose-derived mesenchymal stem cell therapy, led to significant strides in treating perianal fistulas and positioned her as a leader in regenerative medicine. She has been instrumental in launching global clinical trials, developing target product profiles (TPP), and submitting regulatory applications for FDA and EMA approvals. With a robust publication record, including 66 papers indexed in PubMed, she continues to contribute to scientific literature, sharing her findings and advancing the field of biomedicine.

🏆 Accolades and Recognition

Dr. Gilaberte’s excellence has been recognized through numerous awards across her roles in clinical development and leadership. Her achievements include multiple awards for her work in the clinical progression of innovative therapies and successful drug submissions to global regulatory bodies. She has received recognition for her strategic contributions to the Darvadstrocel trials and for advancing neuroscience programs in Alzheimer’s disease. Her leadership has earned her high regard in the industry, with acknowledgments from institutions and colleagues alike.

🌍 Impact and Influence

Dr. Gilaberte’s impact extends beyond her immediate professional roles. Her contributions to clinical science have enhanced treatment options for patients with complex diseases, and her leadership has shaped clinical strategies in multinational pharmaceutical companies. She has also promoted effective collaboration across global, cross-functional teams, fostering a diverse and inclusive work environment that prioritizes patient needs. Her initiatives in regulatory compliance, risk management, and data integration have set new standards for clinical operations, solidifying her influence as a thought leader in her field.

📜 Legacy and Future Contributions

Looking ahead, Dr. Gilaberte’s legacy is one of commitment to advancing patient care through innovation, collaboration, and strategic foresight. Her future endeavors are poised to make an enduring impact, with ongoing research and leadership contributions that will shape the future of clinical development. Her philanthropic work, such as building a nursery in Uganda, highlights her dedication to global well-being beyond her professional achievements. Dr. Gilaberte continues to inspire the next generation of clinical researchers, ensuring that her legacy of precision, empathy, and patient-first innovation will endure.

 

Publications

📄 Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial

  • Authors: Esteban Jódar-Gimeno, Jose Luis Pérez-Castrillón, Ján Nociar, Michal Lojka, Dimitar Nikolov, Fernando Cereto-Castro, Snežana Novković, Umberto Tarantino, Nadia Mehsen-Cetre, Paula Arranz, Cristina Martínez Ostalé, Aintzane García-Bea, Inmaculada Gilaberte
  • Journal: Nutrients
  • Year: 2024

📄 Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial

  • Authors: Coimbra, J., Puntes, M., Molina, P., Arranz, P., Sánchez, C.
  • Journal: European Journal of Pharmaceutical Sciences
  • Year: 2024

📄  Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions

  • Authors: Román, M., Ochoa, D., Martin, S., Arranz, P., Sánchez, C.
  • Journal: Drugs in R and D
  • Year: 2024

📄  Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases

  • Authors: Karki, C., Latremouille-Viau, D., Gilaberte, I., Romdhani, H., Lightner, A.L.
  • Journal: PharmacoEconomics
  • Year: 2023

📄  Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn’s Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial

  • Authors: Garcia-Olmo, D., Gilaberte, I., Binek, M., Spinelli, A., Panés, J.
  • Journal: Diseases of the Colon and Rectum
  • Year: 2022

 

Ayomide Afolabi | Agricultural and Biological Sciences | Editorial Board Member

Published on by Book of Award

Mr. Ayomide Afolabi | Agricultural and Biological Sciences | Editorial Board Member

Jovah Farm | Nigeria

Author Profile 

Scopus

Early Academic Pursuits

Ayomide Afolabi, born on March 28, 1996, is a Nigerian advocate of Climate-Smart Agriculture, demonstrating dedication and efficiency in his academic and professional journey. He believes in the sustainability of Climate-Smart Agriculture for enhancing agricultural productivity and achieving food security.

Professional Endeavors

Ayomide has been actively involved in the agriculture sector, managing and producing various crops such as Cucumbers, Kales, Watermelons, Bell peppers, and Tomatoes. His expertise spans open-field and controlled-environment cultivation, seedling management, pest control, and the formulation of nutritional guidelines. Additionally, he engages in sustainable practices, incorporating Gliricidia sepium and Tithonia diversifolia for soil improvement.

Contributions and Research Focus

With a background in Plant Physiology and Crop Production, Ayomide's academic journey at the Federal University of Agriculture, Abeokuta, reflects his commitment to understanding the effects of integrated nutrient management on lowland rice varieties. His work extends beyond conventional farming, embracing hydroponics, aquaculture, and cutting-edge technologies like nano-biotechnological products.

Accolades and Recognition

Ayomide's dedication and academic excellence have been acknowledged with honors like the Senate annual prize for first-class honors graduating students at the Federal University of Agriculture, Abeokuta.

Impact and Influence

Ayomide's impact extends to the global community through initiatives such as the ICTforAg conference and his involvement in advocacy programs like the Zero Food Waste Initiative. He actively contributes to reducing food waste and promoting sustainable agricultural practices.

Legacy and Future Contributions

Ayomide envisions a legacy of promoting sustainable agriculture and addressing global food security challenges. His multifaceted expertise, from traditional farming to cutting-edge technologies, positions him as a catalyst for positive change in the agricultural landscape. In the future, Ayomide aims to continue his impactful contributions, advancing agriculture with a focus on innovation and sustainability.

Notable Publications

Response of lowland rice varieties to integrated nutrient management in a derived Savannah agro-ecology 2023

Nanoscience and technology as a pivot for sustainable agriculture and its One Health approach awareness 2023

The Application of Microbial Inoculants as a Green Tool towards Achieving Sustainable Agriculture 2023